Debiopharm Digitalizes Preclinical Research to Accelerate Drug Development

De-risking therapies for better success in clinical development requires navigating elaborate in vitro and in vivo studies to generate actionable insights regarding therapy efficacy and safety.

In this case study discover how Debiopharm, a Swiss-based, global biopharmaceutical company, extracts maximal value from its preclinical data to drive better decision-making throughout drug development.

By complementing its internal data infrastructure with Genedata Profiler, Debiopharm equipped its scientists with automatic data preparation and specialized analytical applications. This improved Debiopharm’s R&D data interpretation and enables faster delivery of precision medicines to patients worldwide.